Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Genmab

Explore full profile

Differentiated human antibody therapeutics for the treatment of cancer

Copenhagen, DenmarkFounded 1999Biotech & Life Sciences
Valuation $21B Market cap · Aug/2026
Revenue $4.14B Latest reported FY
EBITDA $1.27B Latest reported FY

At a glance

Status
Listed
Founded
1999
Headquarters
Copenhagen, Denmark
Listing
IPO 2000
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom
Analysis Europe's Decacorns & Centicorns — the Map Aug 23, 2026

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Lombard Odier
  • Dansk Erhvervsinvestering
  • Medicxi
  • Apax Partners
  • LODH Immunology Fund
  • BankInvest

Ownership

Share of equity by holder

Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (May/2026).

7.5% BLACKROCK, INC.

“Other / undisclosed” is the 92.5% not attributed to a named shareholder. See the full cap table on Dealroom →

Talent

Book a demo to see the people
Employees mapped 2,989 incl. 52 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 18 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
25 countries with
team presence
🇺🇸 United States39.9%
🇳🇱 Netherlands29.8%
🇩🇰 Denmark22.3%
🇯🇵 Japan3.1%
🇸🇪 Sweden1.1%
Top 5 of 25 shown
Web traffic by country
100K monthly visits
across markets
🇺🇸 United States28.1%
🇩🇰 Denmark26.9%
🇳🇱 Netherlands11.8%
🇯🇵 Japan6.5%
🇦🇺 Australia4.4%
Top 5 markets shown

Patents

Estimated portfolio value
$488M

295 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Genmab was the backer or acquirer, 2024–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Genmab's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Genmab's portfolio, mapped.

        Stage
        Period
        2 of 2 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Genmab on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Genmab on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles